ClinicalTrials.gg
CompletedNCT02998645SOARUpdated Dec 11, 2023Results posted

Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia

A Phase 2 interventional study of eltrombopag and Cyclosporine in Severe Aplastic Anemia, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.

Enrollment
5th of 17
54 · median 36
Started
2017
with 1 other
Phase 2
11 of 17
1 open now
Registered
9th of 17
by date
Lead sponsor
6 of 17
Novartis Pharmaceuticals

Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 2, and was the 9th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing eltrombopag in Anemia, Aplastic, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and safety of eltrombopag in combination with cyclosporine alone as first-line therapy on overall hematologic response

Read the detailed description

This was an interventional phase II, single-arm, multicenter, open-label, study to investigate the efficacy and safety of the combination of eltrombopag and cyclosporine in treatment-naive, adult subjects with severe aplastic anemia (SAA) as first line therapy.

Eligible subjects received eltrombopag and cyclosporine for up to 6 months. Participants who achieved hematologic response any time on or before 6 months were considered as responders; else they were considered as non-responders.

Responders at Month 6 discontinued eltrombopag and started to taper cyclosporine until relapse or Month 24, whichever was early. Responders who relapsed prior to 6 months and non-responders discontinued the treatment at 6 months and were followed-up for 30 days.

Responders who started to taper cyclosporine and relapsed prior to 24 months discontinued cyclosporine and were followed-up for 30 days.

03

Conditions studied

  • Severe Aplastic Anemia

Browse trials for

Keywords

  • severe acquired aplastic anemia
  • SAA
  • first line
  • eltrombopag
  • cyclosporine
  • h-ATG
  • severe aplastic anemia
  • aplastic anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient had signed the (ICF) prior to any screening procedures
  2. Patient was male/female ≥18 years old at the time of informed consent and able to swallow a tablet.
  3. Patient had SAA characterized by:

    1. Bone marrow cellularity \<30% (excluding lymphocytes) and
    2. At least two of the following (peripheral blood):

      • \<500/µL
      • count \<20,000/µL
      • Absolute reticulocyte count \<60,000/µL
  4. Normal defined as the following as determined via the mean of a triplicate ECG

    • Resting heart rate: 50-90 bpm
    • at screening \<450 msec (for male patients), ≤460 msec (for female patients)

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of Fanconi anemia.
  2. Evidence of a clonal hematologic bone marrow disorder on cytogenetics by central review
  3. Prior therapy with cyclosporine, alemtuzumab, rabbit or horse ATG and thrombopoietin receptor (TPO-R) agonists.
  4. to eltrombopag or cyclosporine or their components.
  5. or ALT >3 x .
  6. Serum creatinine, total , or alkaline phosphatase >1.5 x ULN.
  7. Patient with liver cirrhosis.
  8. Patients who were human immune deficiency virus (), virus or surface antigen (HBsAg) positive. HCV-RNA negative patients were allowed to be enrolled.
  9. Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient's ability to consent, be compliant with study procedures, tolerate protocol therapy, or that death within 30 days is likely.
  10. Patients with cancer who were not considered cure, were on active chemotherapeutic treatment or who took drugs with hematological effects.
  11. Administration of an drug within 30 days or 5 half-lives, whichever was longer, preceding the first dose of study treatment.
  12. Pregnancy statements and requirements:

    Pregnancy or nursing (lactating) women Women of , defined as all women physiologically capable of becoming pregnant (or female partners of male patients), unless they were using highly effective methods of contraception during dosing and for 3 months after stopping medication.

  13. Not able to understand the investigation nature of the study or to give .
  14. abnormality including cardiac arrhythmias (e. g. ventricular tachycardia) complete left bundle branch block, high grade atrioventricular block, or inability to determine the interval on the ECG.
  15. Presence of cardiac disease, or family history of idiopathic sudden death or congenital long QT syndrome.
  16. Risk factors for Torsades de Pointe including uncorrected hypokalemia or hypomagnesemia, or use of concomitant medication(s) with a known risk to prolong the QT interval that could not be discontinued or replaced by safe alternative medication per www.qtdrugs.org.
  17. performance status of ≥2.
  18. Patients under the age of 40 must be referred for consideration of bone marrow transplantation (HSCT) if (human leukocyte antigen) HLA matching had been done and a suitable matched sibling donor was available and the patient was willing to undergo transplantation (i.e. patients who did not have a HLA match or were not medically fit, not willing or unable to undergo transplantation were considered for enrollment).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Eltrombopag + cyclosporine

    Participants received eltrombopag (orally, 150 mg once daily for non-Asian participants / 100 mg once daily for participants of Asian ancestry) in combination with cyclosporine (orally, 10.0 mg/kg/day in divided doses every 12 hours) for up to 6 months. Thereafter, responders at Month 6 were treated with cyclosporine until Month 24

    Drug: eltrombopag · Drug: Cyclosporine

Interventions

  • Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.

    Also known as: ETB115

  • Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows: * 6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months * 9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months * 12-24 months: dose was maintained

06

What researchers measure

Primary outcomes

  1. Overall Hematologic Response Rate by 6 Months

    Overall hematologic response rate by 6 months was defined as the percentage of participants with complete response (CR) or partial response (PR) any time on or before 6 months. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * Absolute neutrophil count (ANC) \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L

    Time frame: Up to 6 months

Secondary outcomes

  1. Overall Hematologic Response Rate by 3 Months

    Overall hematologic response rate by 3 months was defined as the percentage of participants with CR or PR any time on or before 3 months. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L

    Time frame: Up to 3 months

  2. Overall Hematologic Response Rate at 12 and 24 Months

    Overall hematologic response rate at 12 and 24 months was defined as the percentage of participants with CR or PR at 12 and 24 months respectively. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC\>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L

    Time frame: 12 and 24 months

  3. Duration of First Hematologic Response

    Duration of first hematologic response is the time from the date of the start of first response to the date of first relapse. Relapse is defined as no longer meeting definition of PR or CR. Kaplan-Meier method was used for the analysis. If no relapse occurred, the participant was censored at the date of last contact. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24. PR was defined as any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL. CR was defined as all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \>1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L

    Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

  4. Relapse Rate by 6 and 24 Months

    Relapse was defined as no longer meeting the definition of PR (and not CR). Relapse rate by 6 months and 24 was defined as the percentage of responders by 6 months who relapsed prior to 6 months or prior to 24 months respectively. Responders by 6 months were participants who achieved CR or PR any time on or before 6 months. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24. PR: any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC\>500/μL * Platelet count\>20 000/μL * Reticulocyte count\>60 000/μL. CR: all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC\>1 000/μL * Platelet count\>100 000/μL * Hemoglobin\>10 g/L

    Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

  5. Percentage of Participants With Evolution to Myelodysplasia, Paroxysmal Nocturnal Hemoglobinuria (PNH) and Leukemia

    The percentage of participants with evolution to myelodysplasia, PNH and acute leukemia occurring at any time during the study. Clonal evolution to myelodysplasia was defined as a new marrow cytogenic abnormality with or without characteristic dysplastic marrow findings. Clonal evolution to leukemia was defined as greater than 20% peripheral blood and/or marrow blasts. Clonal evolution to paroxysmal nocturnal hemoglobinuria (PNH) was defined as a clone at baseline \< 10% that rose to greater than 50% on study. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24

    Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

  6. Percentage of Participants Who Were Red Blood Cells (RBC) Transfusion Independent

    Percentage of participants who were RBC transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no RBC transfusion for at least 56 days. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

    Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

  7. Percentage of Participants Who Were Platelet Transfusion Independent

    Percentage of participants who were platelet transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no platelet transfusion for at least 28 days. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

    Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

  8. Longest Duration of Transfusion Independence (Platelet or RBC)

    Longest duration of transfusion independence (platelet or RBC) by 6 months and by 24 months (responders only). Transfusion independence was defined as no transfusions required in at least a 28-day period for platelet transfusion and at least 56-day period for RBC transfusion. The duration of the longest interval with transfusion independence was summarized using Kaplan-Meier analysis. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24

    Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

  9. Change From Baseline in Scores of Functional Assessment of Cancer Therapy - General (FACT-G) Patient Reported Outcome

    The FACT-G consists of 27-items divided into 4 domains (physical well-being, social well-being, emotional and functional well-being). All items of the FACT-G use a 5 point scale ranging from 0 to 4 with a 0 rating being "not at all" and a 4 rating being "very much". Total FACT-G score is the sum of physical well-being score, social well-being score, emotional well-being score and functional well-being score. Score ranges from 0 to 108, with higher scores indicating better quality of life (QoL). A positive change from baseline indicates improvement in the QoL. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

    Time frame: Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)

  10. Change From Baseline in Scores of FACT - Thrombocytopenia 18 (FACT-TH18) Patient Reported Outcome

    The FACT-TH18 is comprised of FACT-G and a thrombocytopenia specific questionnaire. FACT-G consists of 27-items divided into 4 domains (physical, social, emotional and functional well-being). FACT-TH18 has 18 additional items which asks the patient to rate degree of thrombocytopenia. All items of the FACT-TH18 use a 5 point scale ranging from 0 to 4, with 0 = "not at all" and 4 = "very much". Total FACT-TH18 score is the sum of physical, social, emotional and functional well-being scores, and thrombocytopenia subscale. Score ranges from 0 to 180, with higher scores indicating better QoL. A positive change from baseline indicates improvement in the QoL. Results are presented for responders and non-responders. If any participant achieved hematologic response (CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

    Time frame: Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)

  11. Change From Baseline in Scores of Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT- Fatigue) Patient Reported Outcome

    The FACIT- Fatigue is a 13-item fatigue subscale that asks the patient to rate their degree of tiredness, weakness and fatigue. All items of the FACIT-Fatigue use a 5-point scale ranging from 0 to 4 with a 0 rating being "not at all" and a 4 rating being "very much". Total score ranges from 0 to 52. Negatively worded items were reverse scored before summing so that higher total scores indicate less fatigue. A positive change from baseline indicates improvement. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

    Time frame: Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)

  12. Pharmacokinetic Parameter- Cmax of Eltrombopag When Combined With Cyclosporine

    Cmax is the observed maximum plasma concentration following administration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 microgram/milliliter (ug/mL). Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

    Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose.

  13. Pharmacokinetic Parameter-AUClast of Eltrombopag When Combined With Cyclosporine

    AUClast is the area under the curve calculated to the last quantifiable concentration point (Tlast). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

    Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose

  14. Pharmacokinetic Parameter- AUCtau of Eltrombopag When Combined With Cyclosporine

    AUCtau is the area under the curve calculated to the end of the dosing interval (tau). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

    Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose

  15. Pharmacokinetic Parameter- Ctrough of Eltrombopag When Combined With Cyclosporine

    Ctrough is the pre-dose plasma concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

    Time frame: Week 2 at pre-dose

  16. Pharmacokinetic Parameter- Tmax of Eltrombopag When Combined With Cyclosporine

    Tmax is the time to reach peak or maximum concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

    Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose

  17. Pharmacokinetic Parameter- CLss/F of Eltrombopag When Combined With Cyclosporine

    CLss/F is the apparent systemic (or total body) clearance at steady state from plasma. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

    Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose

07

Results

Posted Dec 11, 2023

Participant flow

The study was conducted across 20 centers in 9 countries.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneEltrombopag + Cyclosporine
Started54
East/southeast asian ethnicity18
Non-east/southeast asian ethnicity36
Completed35
Not completed19
Withdrew: Adverse event6
Withdrew: Death5
Withdrew: Technical problems4
Withdrew: Lack of efficacy2
Withdrew: Progressive disease1
Withdrew: Subject/guardian decision1
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneEltrombopag + Cyclosporine
Started21
Completed11
Not completed10
Withdrew: Lack of efficacy5
Withdrew: Adverse event2
Withdrew: Progressive disease2
Withdrew: Physician decision1

Outcome measures

PrimaryOverall Hematologic Response Rate by 6 Months

Overall hematologic response rate by 6 months was defined as the percentage of participants with complete response (CR) or partial response (PR) any time on or before 6 months. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * Absolute neutrophil count (ANC) \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L

Time frame:
Up to 6 months
Reported as:
Number · Percentage of participants
Overall Hematologic Response Rate by 6 Months
Percentage of participantsEltrombopag + Cyclosporine
Overall Hematologic Response Rate by 6 Months46.3 (32.6 to 60.4)
SecondaryOverall Hematologic Response Rate by 3 Months

Overall hematologic response rate by 3 months was defined as the percentage of participants with CR or PR any time on or before 3 months. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L

Time frame:
Up to 3 months
Reported as:
Number · Percentage of participants
Overall Hematologic Response Rate by 3 Months
Percentage of participantsEltrombopag + Cyclosporine
Overall Hematologic Response Rate by 3 Months40.7 (27.6 to 55.0)
SecondaryOverall Hematologic Response Rate at 12 and 24 Months

Overall hematologic response rate at 12 and 24 months was defined as the percentage of participants with CR or PR at 12 and 24 months respectively. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC\>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L

Time frame:
12 and 24 months
Reported as:
Number · Percentage of participants
Overall Hematologic Response Rate at 12 and 24 Months
Percentage of participantsEltrombopag + Cyclosporine
At 12 months18.5 (9.3 to 31.4)
At 24 months18.5 (9.3 to 31.4)
SecondaryDuration of First Hematologic Response

Duration of first hematologic response is the time from the date of the start of first response to the date of first relapse. Relapse is defined as no longer meeting definition of PR or CR. Kaplan-Meier method was used for the analysis. If no relapse occurred, the participant was censored at the date of last contact. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24. PR was defined as any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL. CR was defined as all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \>1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L

Time frame:
Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Reported as:
Median · Days
Duration of First Hematologic Response
DaysEltrombopag + Cyclosporine
Duration of First Hematologic Response351.0 (99.0 to NA)
SecondaryRelapse Rate by 6 and 24 Months

Relapse was defined as no longer meeting the definition of PR (and not CR). Relapse rate by 6 months and 24 was defined as the percentage of responders by 6 months who relapsed prior to 6 months or prior to 24 months respectively. Responders by 6 months were participants who achieved CR or PR any time on or before 6 months. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24. PR: any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC\>500/μL * Platelet count\>20 000/μL * Reticulocyte count\>60 000/μL. CR: all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC\>1 000/μL * Platelet count\>100 000/μL * Hemoglobin\>10 g/L

Time frame:
Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Reported as:
Number · Percentage of participants
Relapse Rate by 6 and 24 Months
Percentage of participantsEltrombopag + Cyclosporine
By 6 months32.0 (14.9 to 53.5)
By 24 months44.0 (24.4 to 65.1)
SecondaryPercentage of Participants With Evolution to Myelodysplasia, Paroxysmal Nocturnal Hemoglobinuria (PNH) and Leukemia

The percentage of participants with evolution to myelodysplasia, PNH and acute leukemia occurring at any time during the study. Clonal evolution to myelodysplasia was defined as a new marrow cytogenic abnormality with or without characteristic dysplastic marrow findings. Clonal evolution to leukemia was defined as greater than 20% peripheral blood and/or marrow blasts. Clonal evolution to paroxysmal nocturnal hemoglobinuria (PNH) was defined as a clone at baseline \< 10% that rose to greater than 50% on study. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24

Time frame:
Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants With Evolution to Myelodysplasia, Paroxysmal Nocturnal Hemoglobinuria (PNH) and Leukemia
Percentage of participantsEltrombopag + Cyclosporine
Percentage of Participants With Evolution to Myelodysplasia, Paroxysmal Nocturnal Hemoglobinuria (PNH) and Leukemia0
SecondaryPercentage of Participants Who Were Red Blood Cells (RBC) Transfusion Independent

Percentage of participants who were RBC transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no RBC transfusion for at least 56 days. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

Time frame:
Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Reported as:
Count of participants · Participants
Percentage of Participants Who Were Red Blood Cells (RBC) Transfusion Independent
ParticipantsEltrombopag + Cyclosporine
Day 1 to 6 months- Responders17
Day 1 to 24 months- Responders20
Day 1 to 6 months- Non-Responders5
SecondaryPercentage of Participants Who Were Platelet Transfusion Independent

Percentage of participants who were platelet transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no platelet transfusion for at least 28 days. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

Time frame:
Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Reported as:
Count of participants · Participants
Percentage of Participants Who Were Platelet Transfusion Independent
ParticipantsEltrombopag + Cyclosporine
Day 1 to 6 months- Responders25
Day 1 to 24 months- Responders25
Day 1 to 6 months- Non-responders13
SecondaryLongest Duration of Transfusion Independence (Platelet or RBC)

Longest duration of transfusion independence (platelet or RBC) by 6 months and by 24 months (responders only). Transfusion independence was defined as no transfusions required in at least a 28-day period for platelet transfusion and at least 56-day period for RBC transfusion. The duration of the longest interval with transfusion independence was summarized using Kaplan-Meier analysis. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24

Time frame:
Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Reported as:
Median · Days
Longest Duration of Transfusion Independence (Platelet or RBC)
DaysEltrombopag + Cyclosporine
Day 1 to 6 months- RespondersNA (NA to NA)
Day 1 to 24 months- RespondersNA (498.0 to NA)
Day 1 to 6 months- Non-Responders87.0 (48.0 to NA)
SecondaryChange From Baseline in Scores of Functional Assessment of Cancer Therapy - General (FACT-G) Patient Reported Outcome

The FACT-G consists of 27-items divided into 4 domains (physical well-being, social well-being, emotional and functional well-being). All items of the FACT-G use a 5 point scale ranging from 0 to 4 with a 0 rating being "not at all" and a 4 rating being "very much". Total FACT-G score is the sum of physical well-being score, social well-being score, emotional well-being score and functional well-being score. Score ranges from 0 to 108, with higher scores indicating better quality of life (QoL). A positive change from baseline indicates improvement in the QoL. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

Time frame:
Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)
Reported as:
Median · Score on a scale
Change From Baseline in Scores of Functional Assessment of Cancer Therapy - General (FACT-G) Patient Reported Outcome
Score on a scaleEltrombopag + Cyclosporine
Week 2 (Treatment period 1) - Responders-2.0 (-26 to 30)
Week 4 (Treatment period 1) - Responders-3.0 (-22 to 23)
Week 6 (Treatment period 1) - Responders-0.3 (-48 to 30)
Week 8 (Treatment period 1) - Responders0.0 (-25 to 30)
Week 10 (Treatment period 1) - Responders-1.3 (-43 to 33)
Week 12 (Treatment period 1) - Responders0.8 (-40 to 30)
Week 14 (Treatment period 1) - Responders1.0 (-44 to 29)
Week 16 (Treatment period 1) - Responders-2.0 (-51 to 35)
Week 18 (Treatment period 1) - Responders3.0 (-41 to 37)
Week 20 (Treatment period 1) - Responders-1.0 (-46 to 41)
Week 22 (Treatment period 1) - Responders1.0 (-43 to 39)
Week 24 (Treatment period 1) - Responders1.8 (-46 to 35)
Week 26 (Treatment period 1) - Responders1.0 (-51 to 38)
End of treatment period 1 - Responders-1.0 (-51 to 38)
Week 38 (Treatment period 2)- Responders5.7 (-43 to 47)
Week 53 (Treatment period 2)- Responders4.0 (-46 to 42)
Month 24 (Treatment period 2)- Responders22.0 (-50 to 84)
End of treatment period 2 - Responders13.5 (-5 to 47)
Week 2 (Treatment period 1) - Non-Responders-0.3 (-34 to 21)
Week 4 (Treatment period 1) - Non-Responders-1.0 (-42 to 22)
Week 6 (Treatment period 1) - Non-Responders-3.6 (-45 to 17)
Week 8 (Treatment period 1) - Non-Responders1.5 (-36 to 99)
Week 10 (Treatment period 1) - Non-Responders-0.9 (-27 to 25)
Week 12 (Treatment period 1) - Non-Responders-0.3 (-54 to 26)
Week 14 (Treatment period 1) - Non-Responders-0.3 (-39 to 28)
Week 16 (Treatment period 1) - Non-Responders0.3 (-50 to 23)
Week 18 (Treatment period 1) - Non-Responders-2.6 (-45 to 19)
Week 20 (Treatment period 1) - Non-Responders-1.5 (-44 to 22)
Week 22 (Treatment period 1) - Non-Responders-1.0 (-45 to 12)
Week 24 (Treatment period 1) - Non-Responders2.7 (-30 to 18)
Week 26 (Treatment period 1) - Non-Responders-2.7 (-25 to 24)
End of treatment period 1 - Non-Responders-2.0 (-30 to 24)
SecondaryChange From Baseline in Scores of FACT - Thrombocytopenia 18 (FACT-TH18) Patient Reported Outcome

The FACT-TH18 is comprised of FACT-G and a thrombocytopenia specific questionnaire. FACT-G consists of 27-items divided into 4 domains (physical, social, emotional and functional well-being). FACT-TH18 has 18 additional items which asks the patient to rate degree of thrombocytopenia. All items of the FACT-TH18 use a 5 point scale ranging from 0 to 4, with 0 = "not at all" and 4 = "very much". Total FACT-TH18 score is the sum of physical, social, emotional and functional well-being scores, and thrombocytopenia subscale. Score ranges from 0 to 180, with higher scores indicating better QoL. A positive change from baseline indicates improvement in the QoL. Results are presented for responders and non-responders. If any participant achieved hematologic response (CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

Time frame:
Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)
Reported as:
Median · Score on a scale
Change From Baseline in Scores of FACT - Thrombocytopenia 18 (FACT-TH18) Patient Reported Outcome
Score on a scaleEltrombopag + Cyclosporine
Week 2 (Treatment period 1) - Responders2.3 (-43 to 43)
Week 4 (Treatment period 1) - Responders-1.5 (-37 to 54)
Week 6 (Treatment period 1) - Responders8.4 (-62 to 70)
Week 8 (Treatment period 1) - Responders9.0 (-34 to 66)
Week 10 (Treatment period 1) - Responders3.4 (-44 to 73)
Week 12 (Treatment period 1) - Responders9.3 (-45 to 69)
Week 14 (Treatment period 1) - Responders6.4 (-45 to 63)
Week 16 (Treatment period 1) - Responders7.8 (-47 to 68)
Week 18 (Treatment period 1) - Responders13.9 (-46 to 77)
Week 20 (Treatment period 1) - Responders11.8 (-48 to 81)
Week 22 (Treatment period 1) - Responders13.5 (-46 to 81)
Week 24 (Treatment period 1) - Responders14.5 (-48 to 72)
Week 26 (Treatment period 1) - Responders18.2 (-57 to 72)
End of treatment period 1 - Responders13.9 (-57 to 72)
Week 38 (Treatment period 2)- Responders21.7 (-50 to 88)
Week 53 (Treatment period 2)- Responders22.0 (-50 to 84)
Month 24 (Treatment period 2)- Responders35.7 (5 to 95)
End of treatment period 2 - Responders6.9 (-55 to 35)
Week 2 (Treatment period 1) - Non-Responders0.6 (-78 to 39)
Week 4 (Treatment period 1) - Non-Responders2.1 (-77 to 45)
Week 6 (Treatment period 1) - Non-Responders-1.5 (-97 to 42)
Week 8 (Treatment period 1) - Non-Responders2.0 (-54 to 43)
Week 10 (Treatment period 1) - Non-Responders5.2 (-22 to 41)
Week 12 (Treatment period 1) - Non-Responders1.8 (-101 to 49)
Week 14 (Treatment period 1) - Non-Responders2.8 (-64 to 41)
Week 16 (Treatment period 1) - Non-Responders2.1 (-98 to 38)
Week 18 (Treatment period 1) - Non-Responders0.5 (-78 to 27)
Week 20 (Treatment period 1) - Non-Responders2.4 (-68 to 43)
Week 22 (Treatment period 1) - Non-Responders-1.3 (-67 to 39)
Week 24 (Treatment period 1) - Non-Responders0.7 (-31 to 43)
Week 26 (Treatment period 1) - Non-Responders-1.4 (-24 to 41)
End of treatment period 1 - Non-Responders-1.4 (-27 to 41)
SecondaryChange From Baseline in Scores of Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT- Fatigue) Patient Reported Outcome

The FACIT- Fatigue is a 13-item fatigue subscale that asks the patient to rate their degree of tiredness, weakness and fatigue. All items of the FACIT-Fatigue use a 5-point scale ranging from 0 to 4 with a 0 rating being "not at all" and a 4 rating being "very much". Total score ranges from 0 to 52. Negatively worded items were reverse scored before summing so that higher total scores indicate less fatigue. A positive change from baseline indicates improvement. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.

Time frame:
Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)
Reported as:
Median · Score on a scale
Change From Baseline in Scores of Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT- Fatigue) Patient Reported Outcome
Score on a scaleEltrombopag + Cyclosporine
Week 2 (Treatment period 1) - Responders3.0 (-13 to 34)
Week 4 (Treatment period 1) - Responders2.0 (-16 to 22)
Week 6 (Treatment period 1) - Responders4.0 (-22 to 32)
Week 8 (Treatment period 1) - Responders6.0 (-7 to 29)
Week 10 (Treatment period 1) - Responders4.5 (-11 to 30)
Week 12 (Treatment period 1) - Responders5.5 (-11 to 31)
Week 14 (Treatment period 1) - Responders6.5 (-5 to 26)
Week 16 (Treatment period 1) - Responders6.0 (-5 to 28)
Week 18 (Treatment period 1) - Responders7.0 (-5 to 28)
Week 20 (Treatment period 1) - Responders6.0 (-5 to 29)
Week 22 (Treatment period 1) - Responders6.0 (-8 to 33)
Week 24 (Treatment period 1) - Responders6.0 (-5 to 29)
Week 26 (Treatment period 1) - Responders7.0 (-9 to 32)
End of treatment period 1 - Responders6.0 (-9 to 32)
Week 38 (Treatment period 2)- Responders6.0 (-8 to 33)
Week 53 (Treatment period 2)- Responders8.0 (-2 to 41)
Month 24 (Treatment period 2)- Responders9.0 (1 to 31)
End of treatment period 2 - Responders11.5 (-5 to 42)
Week 2 (Treatment period 1) - Non-Responders-0.5 (-23 to 19)
Week 4 (Treatment period 1) - Non-Responders-2.0 (-38 to 20)
Week 6 (Treatment period 1) - Non-Responders0.0 (-43 to 18)
Week 8 (Treatment period 1) - Non-Responders-1.0 (-27 to 14)
Week 10 (Treatment period 1) - Non-Responders0.5 (-25 to 16)
Week 12 (Treatment period 1) - Non-Responders-1.0 (-42 to 15)
Week 14 (Treatment period 1) - Non-Responders-1.5 (-43 to 16)
Week 16 (Treatment period 1) - Non-Responders-0.5 (-46 to 15)
Week 18 (Treatment period 1) - Non-Responders-6.0 (-43 to 15)
Week 20 (Treatment period 1) - Non-Responders-6.0 (-45 to 22)
Week 22 (Treatment period 1) - Non-Responders-4.0 (-45 to 15)
Week 24 (Treatment period 1) - Non-Responders-7.0 (-19 to 12)
Week 26 (Treatment period 1) - Non-Responders-8.0 (-19 to 15)
End of treatment period 1 - Non-Responders-4.0 (-19 to 15)
SecondaryPharmacokinetic Parameter- Cmax of Eltrombopag When Combined With Cyclosporine

Cmax is the observed maximum plasma concentration following administration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 microgram/milliliter (ug/mL). Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

Time frame:
Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose.
Reported as:
Geometric mean · microgram/milliliter (ug/mL)
Pharmacokinetic Parameter- Cmax of Eltrombopag When Combined With Cyclosporine
microgram/milliliter (ug/mL)Eltrombopag + Cyclosporine
East/Southeast Asian ethnicity29.1 ± 43.5
Non-East/Southeast Asian ethnicity38.7 ± 38.0
SecondaryPharmacokinetic Parameter-AUClast of Eltrombopag When Combined With Cyclosporine

AUClast is the area under the curve calculated to the last quantifiable concentration point (Tlast). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

Time frame:
Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose
Reported as:
Geometric mean · hour*microgram/milliliter (h*ug/mL)
Pharmacokinetic Parameter-AUClast of Eltrombopag When Combined With Cyclosporine
hour*microgram/milliliter (h*ug/mL)Eltrombopag + Cyclosporine
East/Southeast Asian ethnicity583 ± 38.3
Non-East/Southeast Asian ethnicity702 ± 59.9
SecondaryPharmacokinetic Parameter- AUCtau of Eltrombopag When Combined With Cyclosporine

AUCtau is the area under the curve calculated to the end of the dosing interval (tau). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

Time frame:
Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose
Reported as:
Geometric mean · hour*microgram/milliliter (h*ug/mL)
Pharmacokinetic Parameter- AUCtau of Eltrombopag When Combined With Cyclosporine
hour*microgram/milliliter (h*ug/mL)Eltrombopag + Cyclosporine
East/Southeast Asian ethnicity686 ± 32.4
Non-East/Southeast Asian ethnicity727 ± 33.0
SecondaryPharmacokinetic Parameter- Ctrough of Eltrombopag When Combined With Cyclosporine

Ctrough is the pre-dose plasma concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

Time frame:
Week 2 at pre-dose
Reported as:
Geometric mean · microgram/milliliter (ug/mL)
Pharmacokinetic Parameter- Ctrough of Eltrombopag When Combined With Cyclosporine
microgram/milliliter (ug/mL)Eltrombopag + Cyclosporine
East/Southeast Asian ethnicity19.3 ± 45.3
Non-East/Southeast Asian ethnicity27.2 ± 44.1
SecondaryPharmacokinetic Parameter- Tmax of Eltrombopag When Combined With Cyclosporine

Tmax is the time to reach peak or maximum concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

Time frame:
Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose
Reported as:
Median · Hours
Pharmacokinetic Parameter- Tmax of Eltrombopag When Combined With Cyclosporine
HoursEltrombopag + Cyclosporine
East/Southeast Asian ethnicity5.79 (1.93 to 8.00)
Non-East/Southeast Asian ethnicity3.75 (0.00 to 8.00)
SecondaryPharmacokinetic Parameter- CLss/F of Eltrombopag When Combined With Cyclosporine

CLss/F is the apparent systemic (or total body) clearance at steady state from plasma. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.

Time frame:
Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose
Reported as:
Geometric mean · milliliter/hour (mL/h)
Pharmacokinetic Parameter- CLss/F of Eltrombopag When Combined With Cyclosporine
milliliter/hour (mL/h)Eltrombopag + Cyclosporine
East/Southeast Asian ethnicity146 ± 32.4
Non-East/Southeast Asian ethnicity206 ± 33.0

Adverse events

Collected over From day of first dose of study medication to 30 days after last dose of study medication, assessed up to 25 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag + Cyclosporine8/54 (14.8%)27/54 (50%)47/54 (87%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventEltrombopag + Cyclosporine
Febrile neutropeniaBlood and lymphatic system disorders10/54
PyrexiaGeneral disorders2/54
Drug-induced liver injuryHepatobiliary disorders2/54
COVID-19Infections and infestations2/54
Septic shockInfections and infestations2/54
HyperkalaemiaMetabolism and nutrition disorders2/54
Cardiac arrestCardiac disorders1/54
Dental cariesGastrointestinal disorders1/54
Gastric dysplasiaGastrointestinal disorders1/54
HaematocheziaGastrointestinal disorders1/54
Most frequent other events
Showing 10 of 53
Most frequent other events
EventEltrombopag + Cyclosporine
Blood bilirubin increasedInvestigations22/54
NauseaGastrointestinal disorders16/54
DiarrhoeaGastrointestinal disorders12/54
Alanine aminotransferase increasedInvestigations12/54
VomitingGastrointestinal disorders11/54
Aspartate aminotransferase increasedInvestigations10/54
Blood creatinine increasedInvestigations10/54
HypomagnesaemiaMetabolism and nutrition disorders10/54
HeadacheNervous system disorders10/54
Oedema peripheralGeneral disorders8/54

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Eltrombopag + Cyclosporine
Mean52.0 ± 17.88
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag + Cyclosporine
Female20
Male34
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eltrombopag + Cyclosporine
Hispanic or Latino22
Southeast Asian11
East Asian7
West Asian5
Other4
South Asian3
Mixed ethnicity1
Not reported1
08

Study locations

20 sites
  • Novartis Investigative Site
    Ribeirao Preto, SP 14048-900, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 01323-900, Brazil
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Hyderabad, Telangana 500082, India
  • Novartis Investigative Site
    Vellore, India
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Brescia, BR 25123, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Mexico D F, Ciudad De Mexico 06726, Mexico
  • Novartis Investigative Site
    Monterrey, Nuevo Leon 64460, Mexico
  • Novartis Investigative Site
    Puebla, 72000, Mexico
  • Novartis Investigative Site
    San Sebastian, Pais Vasco 20080, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Istanbul, 34890, Turkey
  • Novartis Investigative Site
    Samsun, 55139, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Nov 2020, 41 months.

Results were first posted in Dec 2023, 3 years 1 month after primary completion.

Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2016
First posted
Dec 20, 2016
StartActual
May 11, 2017
Primary completionActual
Nov 3, 2020
CompletionActual
May 30, 2022
Results first posted
Dec 11, 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02998645
Responsible party
Sponsor
First posted
Dec 20, 2016
Start date
May 11, 2017
Primary completion
Nov 3, 2020
Completion
May 30, 2022
Results posted
Dec 11, 2023
Last update
Dec 11, 2023

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eltrombopag · Cyclosporine

Start the discussion